Logo image of CLSK

CLEANSPARK INC (CLSK) Stock Fundamental Analysis

NASDAQ:CLSK - Nasdaq - US18452B2097 - Common Stock - Currency: USD

9.11  -0.75 (-7.61%)

Premarket: 9.31 +0.2 (+2.2%)

Fundamental Rating

4

CLSK gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 282 industry peers in the Software industry. While CLSK seems to be doing ok healthwise, there are quite some concerns on its profitability. CLSK is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLSK has reported negative net income.
CLSK had a negative operating cash flow in the past year.
CLSK had negative earnings in each of the past 5 years.
CLSK had negative operating cash flow in 4 of the past 5 years.
CLSK Yearly Net Income VS EBIT VS OCF VS FCFCLSK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -7.36%, CLSK perfoms like the industry average, outperforming 43.62% of the companies in the same industry.
The Return On Equity of CLSK (-10.34%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -7.36%
ROE -10.34%
ROIC N/A
ROA(3y)-12.83%
ROA(5y)-29.98%
ROE(3y)-14.38%
ROE(5y)-38.48%
ROIC(3y)N/A
ROIC(5y)N/A
CLSK Yearly ROA, ROE, ROICCLSK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

CLSK has a Gross Margin of 51.98%. This is in the lower half of the industry: CLSK underperforms 66.31% of its industry peers.
CLSK's Gross Margin has improved in the last couple of years.
CLSK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.33%
GM growth 5Y29.35%
CLSK Yearly Profit, Operating, Gross MarginsCLSK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

4

2. Health

2.1 Basic Checks

CLSK does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLSK has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CLSK has been increased compared to 5 years ago.
The debt/assets ratio for CLSK is higher compared to a year ago.
CLSK Yearly Shares OutstandingCLSK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
CLSK Yearly Total Debt VS Total AssetsCLSK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 2.27 indicates that CLSK is not a great score, but indicates only limited risk for bankruptcy at the moment.
CLSK's Altman-Z score of 2.27 is in line compared to the rest of the industry. CLSK outperforms 53.19% of its industry peers.
CLSK has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
CLSK has a Debt to Equity ratio of 0.34. This is in the lower half of the industry: CLSK underperforms 60.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z 2.27
ROIC/WACCN/A
WACC10.97%
CLSK Yearly LT Debt VS Equity VS FCFCLSK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 8.67 indicates that CLSK has no problem at all paying its short term obligations.
CLSK has a Current ratio of 8.67. This is amongst the best in the industry. CLSK outperforms 93.26% of its industry peers.
CLSK has a Quick Ratio of 8.67. This indicates that CLSK is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 8.67, CLSK belongs to the best of the industry, outperforming 93.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.67
Quick Ratio 8.67
CLSK Yearly Current Assets VS Current LiabilitesCLSK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for CLSK have decreased strongly by -222.22% in the last year.
Looking at the last year, CLSK shows a very strong growth in Revenue. The Revenue has grown by 89.48%.
The Revenue has been growing by 142.70% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-222.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-184.48%
Revenue 1Y (TTM)89.48%
Revenue growth 3Y112.85%
Revenue growth 5Y142.7%
Sales Q2Q%62.53%

3.2 Future

CLSK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 163.11% yearly.
The Revenue is expected to grow by 44.43% on average over the next years. This is a very strong growth
EPS Next Y1439.62%
EPS Next 2Y303.47%
EPS Next 3Y163.11%
EPS Next 5YN/A
Revenue Next Year96.05%
Revenue Next 2Y62.72%
Revenue Next 3Y44.43%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
CLSK Yearly Revenue VS EstimatesCLSK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
CLSK Yearly EPS VS EstimatesCLSK Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

CLSK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 7.99, the valuation of CLSK can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CLSK indicates a rather cheap valuation: CLSK is cheaper than 93.97% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.10. CLSK is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 7.99
CLSK Price Earnings VS Forward Price EarningsCLSK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CLSK is valued cheaply inside the industry as 80.85% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 21.5
CLSK Per share dataCLSK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CLSK's earnings are expected to grow with 163.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y303.47%
EPS Next 3Y163.11%

More info and screens

0

5. Dividend

5.1 Amount

CLSK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEANSPARK INC

NASDAQ:CLSK (5/28/2025, 8:00:00 PM)

Premarket: 9.31 +0.2 (+2.2%)

9.11

-0.75 (-7.61%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-07 2025-08-07/amc
Inst Owners54.13%
Inst Owner Change18.35%
Ins Owners2.32%
Ins Owner Change-3.68%
Market Cap2.56B
Analysts82.67
Price Target19.96 (119.1%)
Short Float %31.68%
Short Ratio3.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.02
Dividend Growth(5Y)N/A
DP-4.08%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-153.14%
Min EPS beat(2)-403.92%
Max EPS beat(2)97.65%
EPS beat(4)1
Avg EPS beat(4)-174.62%
Min EPS beat(4)-403.92%
Max EPS beat(4)97.65%
EPS beat(8)4
Avg EPS beat(8)35.95%
EPS beat(12)6
Avg EPS beat(12)3.83%
EPS beat(16)6
Avg EPS beat(16)-62.8%
Revenue beat(2)1
Avg Revenue beat(2)-1.35%
Min Revenue beat(2)-7.4%
Max Revenue beat(2)4.69%
Revenue beat(4)1
Avg Revenue beat(4)-2.98%
Min Revenue beat(4)-7.95%
Max Revenue beat(4)4.69%
Revenue beat(8)3
Avg Revenue beat(8)-1.1%
Revenue beat(12)4
Avg Revenue beat(12)-2.59%
Revenue beat(16)4
Avg Revenue beat(16)-6.64%
PT rev (1m)-3.52%
PT rev (3m)-17.96%
EPS NQ rev (1m)21.63%
EPS NQ rev (3m)-33.75%
EPS NY rev (1m)4.06%
EPS NY rev (3m)95.67%
Revenue NQ rev (1m)-12.64%
Revenue NQ rev (3m)-19.39%
Revenue NY rev (1m)-4.09%
Revenue NY rev (3m)-14.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.99
P/S 4.76
P/FCF N/A
P/OCF N/A
P/B 1.35
P/tB 1.46
EV/EBITDA 21.5
EPS(TTM)-0.29
EYN/A
EPS(NY)1.14
Fwd EY12.51%
FCF(TTM)-2.08
FCFYN/A
OCF(TTM)-1.36
OCFYN/A
SpS1.91
BVpS6.73
TBVpS6.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.36%
ROE -10.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.98%
FCFM N/A
ROA(3y)-12.83%
ROA(5y)-29.98%
ROE(3y)-14.38%
ROE(5y)-38.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.33%
GM growth 5Y29.35%
F-Score1
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA 4.45
Cap/Depr 85.18%
Cap/Sales 37.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.67
Quick Ratio 8.67
Altman-Z 2.27
F-Score1
WACC10.97%
ROIC/WACCN/A
Cap/Depr(3y)65.93%
Cap/Depr(5y)337.91%
Cap/Sales(3y)31.8%
Cap/Sales(5y)89.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-222.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-184.48%
EPS Next Y1439.62%
EPS Next 2Y303.47%
EPS Next 3Y163.11%
EPS Next 5YN/A
Revenue 1Y (TTM)89.48%
Revenue growth 3Y112.85%
Revenue growth 5Y142.7%
Sales Q2Q%62.53%
Revenue Next Year96.05%
Revenue Next 2Y62.72%
Revenue Next 3Y44.43%
Revenue Next 5YN/A
EBIT growth 1Y-47.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year994.95%
EBIT Next 3Y134.9%
EBIT Next 5YN/A
FCF growth 1Y-2529.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1149.55%
OCF growth 3YN/A
OCF growth 5YN/A